KR101019264B1 - Ｎ-(4-클로로-3-메틸-5-이속사졸릴)-2-[2-메틸-4,5-(메틸렌디옥시)페닐아세틸]티오펜-3-술폰아미드 나트륨 염의 다형체 - Google Patents

Ｎ-(4-클로로-3-메틸-5-이속사졸릴)-2-[2-메틸-4,5-(메틸렌디옥시)페닐아세틸]티오펜-3-술폰아미드 나트륨 염의 다형체 Download PDF

Info

Publication number
KR101019264B1
KR101019264B1 KR1020087022438A KR20087022438A KR101019264B1 KR 101019264 B1 KR101019264 B1 KR 101019264B1 KR 1020087022438 A KR1020087022438 A KR 1020087022438A KR 20087022438 A KR20087022438 A KR 20087022438A KR 101019264 B1 KR101019264 B1 KR 101019264B1
Authority
KR
South Korea
Prior art keywords
delete delete
methyl
polymorph
sodium
amount
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
KR1020087022438A
Other languages
English (en)
Korean (ko)
Other versions
KR20080106926A (ko
Inventor
존 에프. 라이히바인
팀 핸슨
Original Assignee
엔싸이시브 파마슈티칼즈 인코퍼레이티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 엔싸이시브 파마슈티칼즈 인코퍼레이티드 filed Critical 엔싸이시브 파마슈티칼즈 인코퍼레이티드
Publication of KR20080106926A publication Critical patent/KR20080106926A/ko
Application granted granted Critical
Publication of KR101019264B1 publication Critical patent/KR101019264B1/ko
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/12—Drugs for genital or sexual disorders; Contraceptives for climacteric disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/02—Antidotes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Cardiology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Endocrinology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Reproductive Health (AREA)
  • Toxicology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Diabetes (AREA)
  • Urology & Nephrology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pulmonology (AREA)
  • Dermatology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
KR1020087022438A 2006-03-13 2007-03-12 Ｎ-(4-클로로-3-메틸-5-이속사졸릴)-2-[2-메틸-4,5-(메틸렌디옥시)페닐아세틸]티오펜-3-술폰아미드 나트륨 염의 다형체 Expired - Fee Related KR101019264B1 (ko)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US78186106P 2006-03-13 2006-03-13
US60/781,861 2006-03-13

Publications (2)

Publication Number Publication Date
KR20080106926A KR20080106926A (ko) 2008-12-09
KR101019264B1 true KR101019264B1 (ko) 2011-03-07

Family

ID=38335653

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020087022438A Expired - Fee Related KR101019264B1 (ko) 2006-03-13 2007-03-12 Ｎ-(4-클로로-3-메틸-5-이속사졸릴)-2-[2-메틸-4,5-(메틸렌디옥시)페닐아세틸]티오펜-3-술폰아미드 나트륨 염의 다형체

Country Status (14)

Country Link
US (1) US20090104265A1 (enExample)
EP (1) EP1996582A2 (enExample)
JP (1) JP2009530279A (enExample)
KR (1) KR101019264B1 (enExample)
CN (1) CN101443329A (enExample)
AU (1) AU2007225206B2 (enExample)
BR (1) BRPI0709384A2 (enExample)
CA (1) CA2644134A1 (enExample)
IL (1) IL193682A0 (enExample)
MX (1) MX2008011843A (enExample)
NZ (1) NZ570943A (enExample)
RU (1) RU2412941C2 (enExample)
WO (1) WO2007106467A2 (enExample)
ZA (1) ZA200807302B (enExample)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090004268A1 (en) * 2007-03-13 2009-01-01 Given Bruce D Methods and Compositions for Treatment of an Interstitial Lung Disease

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5793705A (en) * 1996-09-18 1998-08-11 International Business Machines Corporation Ultrasonic liquid level gauge for tanks subject to movement and vibration
WO2006026395A1 (en) 2004-08-26 2006-03-09 Encysive Pharmaceuticals Endothelin a receptor (eta) antagonists in combination with phosphodiesterase 5 inhibitors (pde5) and uses thereof

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5783705A (en) * 1997-04-28 1998-07-21 Texas Biotechnology Corporation Process of preparing alkali metal salys of hydrophobic sulfonamides
US20030180352A1 (en) * 1999-11-23 2003-09-25 Patel Mahesh V. Solid carriers for improved delivery of active ingredients in pharmaceutical compositions
JP4097893B2 (ja) * 2000-12-05 2008-06-11 株式会社エフ・ティ・エスコーポレーション 対向ターゲット式スパッタ方法及び導電性膜の形成方法
JP2005527523A (ja) * 2002-03-15 2005-09-15 ノバルティス　アクチエンゲゼルシャフト ＡｎｇＩＩ介在性疾病を処置するための４−（４−メチルピペラジン−１−イルメチル）−Ｎ−［４−メチル−３−（４−ピリジン−３−イル）ピリミジン−２−イル−アミノ］フェニル］−ベンズアミド
GB0223854D0 (en) * 2002-10-12 2002-11-20 Astrazeneca Ab Therapeutic treatment

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5793705A (en) * 1996-09-18 1998-08-11 International Business Machines Corporation Ultrasonic liquid level gauge for tanks subject to movement and vibration
WO2006026395A1 (en) 2004-08-26 2006-03-09 Encysive Pharmaceuticals Endothelin a receptor (eta) antagonists in combination with phosphodiesterase 5 inhibitors (pde5) and uses thereof

Also Published As

Publication number Publication date
MX2008011843A (es) 2008-10-02
WO2007106467A3 (en) 2007-10-25
JP2009530279A (ja) 2009-08-27
US20090104265A1 (en) 2009-04-23
RU2412941C2 (ru) 2011-02-27
BRPI0709384A2 (pt) 2011-03-22
CN101443329A (zh) 2009-05-27
AU2007225206B2 (en) 2010-08-05
EP1996582A2 (en) 2008-12-03
CA2644134A1 (en) 2007-09-20
ZA200807302B (en) 2009-11-25
IL193682A0 (en) 2009-05-04
RU2008136316A (ru) 2010-04-20
AU2007225206A1 (en) 2007-09-20
NZ570943A (en) 2010-09-30
WO2007106467A2 (en) 2007-09-20
KR20080106926A (ko) 2008-12-09

Similar Documents

Publication Publication Date Title
CA2722248C (en) Hydrogensulfate salt of 2-acetoxy-5-(a-cyclopropylcarbonyl-2-fluorobenzyl)-4,5,6,7-tetrahydrothieno[3,2-c]pyridine and its preparation
CA2896060A1 (en) Substituted pyridine-2-carboxamide compounds as apoptosis signal-regulating kinase inhibitors
US20080076812A1 (en) Formulations of sitaxsentan sodium
KR20090035741A (ko) Ｎ-(2-아세틸-4,6-디메틸페닐)-3-｛[(3,4-디메틸-5-이속사졸릴)-아미노]술포닐｝-2-티오펜-카르복스아미드의 다형체
KR101019264B1 (ko) Ｎ-(4-클로로-3-메틸-5-이속사졸릴)-2-[2-메틸-4,5-(메틸렌디옥시)페닐아세틸]티오펜-3-술폰아미드 나트륨 염의 다형체
US20080026061A1 (en) Crystalline N-(4-chloro-3-methyl-5-isoxazolyl)-2-[2-methyl-4.5-(methylenedioxy)phenylacetyl]-thiophene-3-sulfonamide
KR20190126291A (ko) 옥사진 유도체를 포함하는 약제학적 조성물 및 알츠하이머병의 치료 또는 예방에 있어서 그의 용도
HK1127057A (en) Polymorphs of n-(4-chloro-3-methyl-5-isoxazolyl)2-[2-methyl-4,5-(methylenedioxy) phenylacetyl]thiophene-3-sulfonamide, sodium salt
HK1137172A (en) Polymorphs of n-(2-acetyl-4,6-dimethylphenyl)-3-{[3,4dimethyl-5-isoxazolyl)-amino]sulfonyl}-2-thiophene-carboxamide
US20030004199A1 (en) Method for preventing or treating pulmonary inflammation by administering an endothelin antagonist
US20080317858A1 (en) Formulations of n-(2-acetyl-4,6-dimethylphenyl)-3--2-thiophenecarboxamide
WO2018130226A1 (zh) 利奥西呱的新晶型及其制备方法和用途
HK1125316A (en) Formulations of sitaxsentan sodium
HK1115382A (en) Polymorphs of ethyl 3-[(2-{[4-(hexyloxycarbonylamino-iminomethyl)phenylamino]methyl}-1-methyl-1h-benzimidazole-5-carbonyl)pyridin-2-ylamino]propionate

Legal Events

Date Code Title Description
A201 Request for examination
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

R18-X000 Changes to party contact information recorded

St.27 status event code: A-3-3-R10-R18-oth-X000

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

St.27 status event code: A-1-2-D10-D22-exm-PE0701

GRNT Written decision to grant
PR0701 Registration of establishment

St.27 status event code: A-2-4-F10-F11-exm-PR0701

PR1002 Payment of registration fee

St.27 status event code: A-2-2-U10-U12-oth-PR1002

Fee payment year number: 1

PG1601 Publication of registration

St.27 status event code: A-4-4-Q10-Q13-nap-PG1601

LAPS Lapse due to unpaid annual fee
PC1903 Unpaid annual fee

St.27 status event code: A-4-4-U10-U13-oth-PC1903

Not in force date: 20140225

Payment event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

PC1903 Unpaid annual fee

St.27 status event code: N-4-6-H10-H13-oth-PC1903

Ip right cessation event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

Not in force date: 20140225